PHOENIX, Oct. 20,
2022 /PRNewswire/ -- Creative Medical Technology
Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused
on a regenerative approach to immunotherapy, endocrinology,
urology, neurology, and orthopedics, announced today that through
predominantly internal and collaborative development, it has
produced an allogenic Cell Line called AlloStem™, which includes a
Master Cell Bank and a Drug Master File which shall be submitted
for FDA registration.
"The importance of the company creating and developing such
assets, as opposed to licensing agreements with third parties,
provides further de-risking of an important component to many of
our programs, including, but not limited to, the
ImmCelz® immunotherapy platform for multiple diseases,
OvaStem® for Premature Ovarian Failure,
AlloStem™ for Type 1 diabetes, StemSpine® for lower
back pain, and IPSCelz ™ inducible pluripotent stem cell
program in ongoing development with Greenstone Biosciences," said
Timothy Warbington, CEO.
"Drug Master Files, registered with the FDA, are a highly
valuable tool in cross referencing data in Orphan Drug Development
of interventional drug products, Investigational New Drug
Development and Investigational Device Exemptions to the FDA. Drug
Master Files do not expire and are utilized by many pharmaceutical
and biotechnology giants as well as many other industries for their
products, dating back to the 1940s," said Courtney Bartlett DNP,
Director of Clinical Development.
"As our programs roll out, the company intends to publicly
disclose the progress at the appropriate time," Timothy Warbington said further.
About Creative Medical Technology
Holdings
Creative Medical Technology Holdings, Inc. is a biotechnology
company specializing in regenerative medicine/stem cell technology
in the fields of immunotherapy, endocrinology, urology, neurology
and orthopedics and is traded on NASDAQ under the ticker symbol
CELZ. For further information about the company, please
visit www.creativemedicaltechnology.com.
Forward Looking
Statements
NASDAQ Markets has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This
news release may contain forward-looking statements including but
not limited to comments regarding the timing and content of
upcoming clinical trials and laboratory results, marketing efforts,
funding, etc. Forward-looking statements address future events and
conditions and, therefore, involve inherent risks and
uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-develops-allostem-clinical-cell-line-301654351.html
SOURCE Creative Medical Technology Holdings, Inc.